Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Genetic Disease
Study Phase : Preclinical
Sponsor : Dr. Reddy\'s Laboratories
Deal Size : $2.0 million
Deal Type : Financing
Dr. Reddy's Laboratories acquires Preferred A-1 shares of Edity Therapeutics
Details : The financing would be utilized by Edity to further develop its technology platform for intracellular delivery of therapeutic proteins utilizing immune cells in multiple therapeutic areas including gene editing, rare genetic disorders, oncology and infla...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : $2.0 million
December 30, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Genetic Disease
Highest Development Status : Preclinical
Sponsor : Dr. Reddy\'s Laboratories
Deal Size : $2.0 million
Deal Type : Financing
Reset All
